Actively Recruiting

Phase 2
Age: 6Months - 26Years
All Genders
Healthy Volunteers
NCT03779854

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Led by Fred Hutchinson Cancer Center · Updated on 2026-05-14

68

Participants Needed

10

Research Sites

487 weeks

Total Duration

On this page

Sponsors

F

Fred Hutchinson Cancer Center

Lead Sponsor

N

National Cancer Institute (NCI)

Collaborating Sponsor

AI-Summary

What this Trial Is About

This phase II trial studies how well naive T-cell depletion works in preventing chronic graft-versus-host disease in children and young adults with blood cancers undergoing donor stem cell transplant. Sometimes the transplanted white blood cells from a donor attack the body's normal tissues (called graft versus host disease). Removing a particular type of T cell (naive T cells) from the donor cells before the transplant may stop this from happening.

CONDITIONS

Official Title

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Who Can Participate

Age: 6Months - 26Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 6 months to 26 years at the time of consent
  • Diagnosis of acute lymphoblastic leukemia with less than 5% marrow blasts
  • Diagnosis of acute myeloid leukemia with less than 25% marrow blasts
  • Diagnosis of other acute leukemia or related neoplasm with less than 5% marrow blasts
  • Diagnosis of myelodysplastic syndrome with excess blasts and prior cytotoxic induction chemotherapy
  • Candidate for allogeneic hematopoietic cell transplantation as determined by study investigator
  • Planned donor is a matched related or unrelated donor with 8/8 HLA match
  • Planned stem cell product is peripheral blood stem cells or bone marrow
  • Karnofsky or Lansky performance score of 60% or higher
  • Left ventricular ejection fraction of at least 40%
  • Lung function with DLCO at least 60% predicted or oxygen saturation at least 92% if pulmonary function tests cannot be performed
  • Total bilirubin at or below twice the upper limit of normal unless disease- or medication-related
  • ALT and AST at or below twice the upper limit of normal unless disease- or medication-related
  • Serum creatinine within normal range for age or creatinine clearance over 40 mL/min/1.73m2
  • Informed consent or guardian permission obtained
  • Donor is at least 14 years old and available in the United States
  • Donor agrees to donate bone marrow or peripheral blood stem cells
  • Donor meets all applicable eligibility and testing requirements
Not Eligible

You will not qualify if you...

  • Active central nervous system disease not cleared before conditioning
  • Participation in other experimental protocols for GVHD prevention
  • Body weight over 100 kg for matched related donor recipients
  • Body weight over 75 kg for matched unrelated donor recipients without prior discussion
  • HIV positive status
  • Uncontrolled infections not deemed suitable for transplant
  • Life expectancy less than 3 months from non-leukemia or non-myelodysplastic syndrome causes
  • Significant medical conditions making transplant unsuitable
  • Prior allogeneic or autologous hematopoietic cell transplant
  • Pregnancy or breastfeeding in female participants
  • Childbearing age participants unwilling to use birth control or abstain from sexual intercourse during treatment and for 12 months after transplant
  • Known allergy to tacrolimus, fludarabine, or methotrexate

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 10 locations

1

Children's Hospital of Los Angeles

Los Angeles, California, United States, 90027

Actively Recruiting

2

Children's National Medical Center

Washington D.C., District of Columbia, United States, 200100

Withdrawn

3

Children's Healthcare of Atlanta

Atlanta, Georgia, United States, 30329

Not Yet Recruiting

4

University of Iowa/Holden Comprehensive Cancer Center

Iowa City, Iowa, United States, 52242

Actively Recruiting

5

Dana Farber / Boston Children's Hospital

Boston, Massachusetts, United States, 02115

Not Yet Recruiting

6

UH Rainbow Babies and Children's Hospital (University Hospitals Cleveland Medical Center)

Cleveland, Ohio, United States, 44106

Not Yet Recruiting

7

Cleveland Clinic Foundation

Cleveland, Ohio, United States, 44195

Actively Recruiting

8

Oregon Health and Science University

Portland, Oregon, United States, 97239

Actively Recruiting

9

Children's Hospital of Pittsburgh of UPMC

Pittsburgh, Pennsylvania, United States, 15224

Actively Recruiting

10

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, United States, 98109

Actively Recruiting

Loading map...

Research Team

M

Marie Bleakley

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant | DecenTrialz